HOME > Our Business > Prescription Pharmaceutical > Research and Development

Research and Development

Promoting strategic development targeting the global market by developing highly unique new drugs.

Promoting strategic development toward future growth

New drug development is heating up throughout the world. In the future, it is unlikely that a manufacturer will be able to survive without developing and continuously launching highly original new drugs. Our basic R&D strategy is to develop new drugs with a high standard of originality, focusing on ''infectious diseases,'' ''orthopedic disorders,'' ''CNS,'' and ''metabolic diseases.'' To achieve this goal, we have organized and improved our domestic R&D infrastructure, steadily strengthening our capability to develop new drugs for the global market.

While promoting in-house new drug development, we also promote alliances with Japanese and overseas companies to ''improve pipelines.'' Taisho Pharmaceutical Co., Ltd. began a partnership with Toyama Chemical for the domestic sale of prescription pharmaceutical products in 2002. In addition, in 2008, Taisho Pharmaceutical, FUJIFILM Holdings, and Toyama Chemical reached a basic agreement on strategic capital and business alliances, and Taisho Pharmaceutical further strengthened its capital alliance with Toyama Chemical. The purpose of the alliance is to accelerate the speed of new drug development through strengthening ties with Toyama Chemical that has many promising new drugs. As a result of the joint development, a new type of quinolone antibacterial agent, ''Geninax'' was launched in 2007. Thanks to the alliance with Toyama Chemical, there has been a realization of synergy with the quality and speed of the development of new drugs improving.

Technology to search compounds having activities against the target molecule from hundreds of thousands of compounds: automation of high throughput screening process.

A measuring instrument to digitize the activities of target enzymes and receptors. Using the numerical values, promising compounds are then narrowed down.

Observing a 60nm (nano micron) biological specimen with a transmission electron microscope. Minute objects not visible with an optical microscope can be observed.

All research from basic research and exploratory research to research and development of OTC drugs and prescription pharmaceutical products are carried out in the Omiya Research Center.